Stock SANOFI SANOFI INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sanofi India Limited NSE India S.E.

Equities

SANOFI

INE058A01010

Market Closed - NSE India S.E.
Other stock markets
 07:43:49 2024-05-03 am EDT 		5-day change 1st Jan Change
8,624 INR -0.62% Intraday chart for Sanofi India Limited +4.23% +6.90%
Apr. 15 Sanofi India Limited Announces Appointment of Flovie Martins as Head of Corporate Communications and Corporate Social Responsibility CI
Mar. 28 Sanofi India Limited Announces Resignation of Marc-Antoine Lucchini as Non-Executive Director from the Board of Directors, Member of the Nomination and Remuneration Committee CI

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • With an expected P/E ratio at 33.68 and 30.95 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
SANOFI INDIA LIMITED Stock Sanofi India Limited
+6.90% 2.38B -
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.98% 43.48B
B-
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+20.67% 22.65B
B+
SANDOZ GROUP AG Stock Sandoz Group AG
+14.56% 14.73B -
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+44.72% 12.04B
B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-8.37% 7.08B
B+
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B - -
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B - -
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+11.90% 5.47B
B+
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. Stock Shenzhen Salubris Pharmaceuticals Co., Ltd.
-2.27% 4.81B
D+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. SANOFI Stock
  4. SANOFI Stock
  5. Ratings Sanofi India Limited